These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33665949)

  • 1. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?
    Burzi L; Repetto F; Ramondetta A; Rozzo G; Licciardello M; Ribero S; Quaglino P; Dapavo P
    Dermatol Ther; 2021 May; 34(3):e14930. PubMed ID: 33665949
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Arias-Santiago S; Molina-Leyva A
    Dermatol Ther; 2020 May; 33(3):e13456. PubMed ID: 32319172
    [No Abstract]   [Full Text] [Related]  

  • 3. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab.
    Garcia-Melendo C; Vilarrasa E; Cubiró X; Bittencourt F; Puig L
    Dermatol Ther; 2020 Nov; 33(6):e14180. PubMed ID: 32790040
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast.
    Agud-Dios M; Arroyo-Andrés J; Rubio-Muñiz C; Postigo-Lorente C
    Dermatol Ther; 2022 Oct; 35(10):e15743. PubMed ID: 35904888
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.
    Kearney N; Byrne N; Kirby B; Hughes R
    Clin Exp Dermatol; 2020 Jul; 45(5):618-619. PubMed ID: 32068912
    [No Abstract]   [Full Text] [Related]  

  • 8. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 9. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.
    Casseres RG; Kahn JS; Her MJ; Rosmarin D
    J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567
    [No Abstract]   [Full Text] [Related]  

  • 10. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.
    Melgosa Ramos FJ; García Ruiz R; Mateu Puchades A; Alfageme Roldán F
    Dermatol Ther; 2022 Jul; 35(7):e15558. PubMed ID: 35510581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe hidradenitis Suppurativa and Fistulizing Crohn's disease with Guselkumab.
    Croitoru DO; Seigel K; Nathanielsz N; Elsawi R; Silverberg MS; Piguet V; Sibbald C
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e563-e565. PubMed ID: 35224787
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe hidradenitis suppurativa successfully treated with secukinumab.
    Głowaczewska A; Szepietowski JC; Matusiak Ł
    Dermatol Ther; 2020 Nov; 33(6):e13845. PubMed ID: 32544258
    [No Abstract]   [Full Text] [Related]  

  • 13. Association and management of Crohn's disease plus hidradenitis suppurativa.
    dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
    Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
    [No Abstract]   [Full Text] [Related]  

  • 14. Guselkumab in the treatment of severe hidradenitis suppurativa.
    Kovacs M; Podda M
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e140-e141. PubMed ID: 30480844
    [No Abstract]   [Full Text] [Related]  

  • 15. Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa.
    Molinelli E; Sapigni C; Simonetti O; Radi G; Gambini D; Maurizi A; Rizzetto G; D'Agostino GM; Offidani A
    Dermatol Ther; 2022 Aug; 35(8):e15645. PubMed ID: 35716015
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of moderate to severe hidradenitis suppurativa.
    Kimball AB; Gu Y; Okun M
    Ann Intern Med; 2013 Jul; 159(1):72-3. PubMed ID: 23817710
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of moderate to severe hidradenitis suppurativa.
    Prasad V
    Ann Intern Med; 2013 Jul; 159(1):72. PubMed ID: 23817709
    [No Abstract]   [Full Text] [Related]  

  • 18. Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.
    Megna M; Ruggiero A; Di Guida A; Patrì A; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Jul; 33(4):e13756. PubMed ID: 32495491
    [No Abstract]   [Full Text] [Related]  

  • 19. Certolizumab pegol for hidradenitis suppurativa: Case report and literature review.
    Holm JG; Jørgensen AR; Yao Y; Thomsen SF
    Dermatol Ther; 2020 Nov; 33(6):e14494. PubMed ID: 33135826
    [No Abstract]   [Full Text] [Related]  

  • 20. Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.
    Tas-Aygar G; Gonul M; Ozcan I; Ayli MD; Ertoy-Baydar D
    Dermatol Ther; 2020 Nov; 33(6):e14205. PubMed ID: 32829493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.